As part of the world’s largest healthcare company, Janssen Research & Development is the worldwide pharmaceutical research division of Janssen Pharmaceutica NV , one of the companies from the Janssen Pharmaceutical Companies of Johnson&Johnson specialized in research into small molecules. Collectively, Janssen Pharmaceutica NV and its affiliates represent the largest segment of Johnson & Johnson’s pharmaceutical research; our R&D effort extends to more than 70 countries worldwide. Within the Janssen Pharmaceutical Companies of Johnson & Johnson, Janssen Pharmaceutica NV is a worldwide Center of Excellence for integrated R&D, production and general services. With over 80 drugs to its name, the company is one of the most innovative in the world and its products are used worldwide in human and veterinary medicine and for material protection. The company is involved in a wide variety of areas, such as gastroenterology, diseases affecting the central nervous system, oncology, immunology and infectious diseases.
Janssen Research & Development has important research investments, ongoing and planned on short and longer term, in the areas of gastrointestinal diseases like inflammatory bowel disease (IBD) and colorectal cancer (CRC), as well as in the field of microbiome interactions.
As a pharmaceutical R&D company, the Janssen Pharmaceutical Companies of Johnson & Johnson is among the top ten pharma companies in the world. Contributing to this project will be especially the department Preclinical Development & Safety (Toxicology/Translational Safety Sciences, Pathology and Pharmacokinetics Dynamics & Metabolism) located amongst others in Beerse, Belgium.
Janssen is also involved in the following projects related to TransQST: eTOX, MIP-DILI.